Agents targeting genetic aberrations, such as like fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, mutations in isocitrate dehydrogenase (NADP+) 1 (IDH1) and isocitrate dehydrogenase (NADP+) 2 (IDH2), or HER2 amplification, have shown promise in clinical trials222, tailored to the tumour's molecular profile. This evidence concerns the gene IDH1 and neoplasm.